News

Queen Sofía of Spain awarded for becoming Global Ambassador

15 May 2019 – ADI's Chief Executive Paola Barbarino presented Her Majesty Queen Sofía of Spain with an award for becoming ADI’s Global Ambassador at the 3rd Dementia Forum X meeting at the Royal Palace of Stockholm. [read more]

ADI, GADAA and Alzheimer's Pakistan launch report on Dementia in Humanitarian Settings

9 May 2019 – A pioneering new report by ADI, The Global Alzheimer’s & Dementia Action Alliance (GADAA) and Alzheimer's Pakistan has revealed that people with dementia are being ignored in times of humanitarian crisis. [read more]

A new type of dementia identified?

3 May 2019 - A paper published in the journal Brain (30 April 2019) has identified a brain disorder that appears to mimic the clinical features of Alzheimer’s disease. Known as LATE (Limbic-predominant Age-related TDP-43 Encephalopathy) it appears to be linked to the accumulation of a protein, TDP-43, in the brain, while Alzheimer's disease is more commonly linked to two other brain proteins - amyloid and tau. [read more]

ADI invites you to their side event at the 72nd World Health Assembly

1 May 2019 - Alzheimer's Disease International (ADI) is delighted to invite you to a side event at the 72nd World Health Assembly, moderated by Chief Executive Paola Barbarino. [read more]

Survey on attitudes around dementia now open

15 April 2019 – ADI's survey on attitudes around dementia is now open and we want to hear what YOU think. The survey will form the basis for the World Alzheimer Report 2019, to be released in September. It will only take around 10 minutes of your time but completing it will benefit people with dementia all over the world. [Read more] 

Queen Silvia of Sweden awarded for becoming Global Ambassador

3 April 2019 – ADI's Chief Executive Paola Barbarino presented Her Majesty Queen Silvia of Sweden with an award for becoming ADI’s Global Ambassador at the Jubilee event for the Queen Silvia Nursing Award at the Royal Palace of Stockholm. [read more]

Biogen and Eisai remain committed after discontinuation of ENGAGE and EMERGE programmes

22 March 2019 – Pharmaceutical companies Biogen and Eisai have announced the discontinuation of two Phase 3 trials of aducanumab. The decision came after analysis by an independent monitoring committee indicated the trials were unlikely to succeed. Biogen and Eisai will continue to investigate other treatments for Alzheimer’s disease, including anti-amyloid treatment BAN2401. [read more]

Global Perspective Newsletter for February 2019

The February 2019 edition of our Global Perspective Newsletter is now available. Read the latest news from ADI, our partners and member associations, including updates from the WHO Executive Board; the Korean National Institute (KNID)'s symposium; Dementia Alliance International, and much more. [read it now]

El Informe Mundial sobre el Alzheimer 2018 ya está disponible en español

31 de enero de 2019 – El Informe Mundial sobre el Alzheimer 2018 ya está disponible en español en nuestro sitio web. El informe aborda cuestiones claves en la investigación de la demencia, sobre ciencia básica, diagnóstico, descubrimiento de fármacos, reducción de riesgos, epidemiología y cuidados. Descubre lo que tienen que decir los principales investigadores de la demencia a nivel mundial. [Lea más] [read more]

Roche remain committed after discontinuing CREAD programme

30 January 2019 – Pharmaceutical company Roche has announced the discontinuation of their CREAD programme. This was following the finding of two Phase III trials that crenezumab, a possible new drug treatment for Alzheimer’s disease, was not expected to meet its efficacy targets. The Alzheimer’s Prevention Initiative (API) will continue to investigate crenezumab in a pivotal trial to prevent Alzheimer’s disease in healthy people with familial Alzheimer’s disease. Crenezumab was discovered by Swiss biotechnology company AC Immune SA and developed by Roche. [read more]